The grants cover an aggregate of 36,000 shares of common stock, each carrying an exercise price of $64.84, mirroring the closing price of Nektar stock on the grant date. These options operate under an eight-year term and follow a standard four-year vesting schedule. Specifically, 25% of the shares vest on the first anniversary of the hire date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent upon continued employment.
Nektar Therapeutics Issues Stock Options to New Hires
San Francisco-based Nektar Therapeutics has granted non-qualified stock options to 23 newly hired employees as a material inducement for their employment. The move, finalized on July 20, 2026, utilizes the company’s 2025 Inducement Plan to attract talent as the biotech firm advances its clinical-stage pipeline.
This compensation strategy aligns with Nasdaq Listing Rule 5635(c)(4), which permits equity awards for individuals newly joining the organization. Nektar, currently focused on developing treatments for autoimmune and chronic inflammatory diseases, continues to build its clinical programs, including its lead candidate, rezpegaldesleukin, and several preclinical bivalent programs.
Comments (0)
No comments yet. Be the first!